万德替尼治疗不可切除甲状腺髓样癌的疗效

Hiroyuki Yamada, Tomohito Fuke, Kohei Fukukita, Mamika Kaneko, Masahiro Sawa, K. Ueda, D. Kobayashi
{"title":"万德替尼治疗不可切除甲状腺髓样癌的疗效","authors":"Hiroyuki Yamada, Tomohito Fuke, Kohei Fukukita, Mamika Kaneko, Masahiro Sawa, K. Ueda, D. Kobayashi","doi":"10.5981/jjhnc.45.71","DOIUrl":null,"url":null,"abstract":"Surgical therapy is the main strategy for medullary thyroid cancer, but there is no effective therapy for resectable advanced cases. Vandetanib is a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling. We experienced a case medicated by Vandetanib for medullary thyroid cancer. A 55-year-old female was diagnosed with medullary thyroid cancer by aspiration cytology of a thyroid tumor and needle biopsy histology. Since FDG-PET showed multiple bone metastases, she was treated with Vandetanib. Serum calcitonin and carcinoembryonic antigen decreased after withdrawal of the medication, and US showed decreased size of the thyroid tumor and cervical lymph nodes similarly. Since PET-CT showed decreased accumulation into these nodules, she was judged to have responded to the treatment. Though Vandetanib is a first-line TKI for unresectable medullary thyroid cancer, the purpose of this therapy is to control progression of the cancer.","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of Vandetanib for unresectable medullary thyroid cancer\",\"authors\":\"Hiroyuki Yamada, Tomohito Fuke, Kohei Fukukita, Mamika Kaneko, Masahiro Sawa, K. Ueda, D. Kobayashi\",\"doi\":\"10.5981/jjhnc.45.71\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Surgical therapy is the main strategy for medullary thyroid cancer, but there is no effective therapy for resectable advanced cases. Vandetanib is a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling. We experienced a case medicated by Vandetanib for medullary thyroid cancer. A 55-year-old female was diagnosed with medullary thyroid cancer by aspiration cytology of a thyroid tumor and needle biopsy histology. Since FDG-PET showed multiple bone metastases, she was treated with Vandetanib. Serum calcitonin and carcinoembryonic antigen decreased after withdrawal of the medication, and US showed decreased size of the thyroid tumor and cervical lymph nodes similarly. Since PET-CT showed decreased accumulation into these nodules, she was judged to have responded to the treatment. Though Vandetanib is a first-line TKI for unresectable medullary thyroid cancer, the purpose of this therapy is to control progression of the cancer.\",\"PeriodicalId\":38497,\"journal\":{\"name\":\"Japanese Journal of Head and Neck Cancer\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Head and Neck Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5981/jjhnc.45.71\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Head and Neck Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5981/jjhnc.45.71","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

手术治疗是治疗甲状腺髓样癌的主要策略,但对于可切除的晚期病例没有有效的治疗方法。Vandetanib是一种每日一次的口服RET激酶、血管内皮生长因子受体和表皮生长因子受体信号传导抑制剂。我们经历了一个用万德替尼治疗甲状腺髓样癌的病例。一个55岁的女性被诊断为甲状腺髓样癌通过甲状腺肿瘤的穿刺细胞学和针活检组织学。由于FDG-PET显示多发骨转移,她接受万德替尼治疗。停药后血清降钙素和癌胚抗原下降,US显示甲状腺肿瘤和颈部淋巴结大小减小。由于PET-CT显示这些结节的积聚减少,因此判断她对治疗有反应。虽然Vandetanib是不可切除的甲状腺髓样癌的一线TKI,但这种治疗的目的是控制癌症的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effectiveness of Vandetanib for unresectable medullary thyroid cancer
Surgical therapy is the main strategy for medullary thyroid cancer, but there is no effective therapy for resectable advanced cases. Vandetanib is a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling. We experienced a case medicated by Vandetanib for medullary thyroid cancer. A 55-year-old female was diagnosed with medullary thyroid cancer by aspiration cytology of a thyroid tumor and needle biopsy histology. Since FDG-PET showed multiple bone metastases, she was treated with Vandetanib. Serum calcitonin and carcinoembryonic antigen decreased after withdrawal of the medication, and US showed decreased size of the thyroid tumor and cervical lymph nodes similarly. Since PET-CT showed decreased accumulation into these nodules, she was judged to have responded to the treatment. Though Vandetanib is a first-line TKI for unresectable medullary thyroid cancer, the purpose of this therapy is to control progression of the cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Japanese Journal of Head and Neck Cancer
Japanese Journal of Head and Neck Cancer Medicine-Otorhinolaryngology
CiteScore
0.10
自引率
0.00%
发文量
7
期刊最新文献
Parotid gland metastases as a diagnostic clue to scalp angiosarcoma: A case report ラロトレクチニブが著効した唾液腺分泌癌の1例 腎細胞癌の甲状腺転移とそれに伴う静脈内腫瘍塞栓に対しTransmanubrial Osteomuscular Sparing Approachで静脈再建を施行した1例 当科における頭頸部癌自家遊離組織移植術症例の術後合併症と対策 頭頸部癌治療後患者の嚥下障害に対する外科的介入について
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1